ストックスクリーナーアプリを入手
96.80
6.00%
5.48
アフターアワーズ：
96.80
前日終値:
$91.32
開ける：
$93.52
24時間の取引高:
3.57M
Relative Volume:
2.75
時価総額：
$47.88B
収益：
$9.91B
当期純損益:
$1.02B
株価収益率:
47.22
EPS:
2.05
ネットキャッシュフロー:
$665.00M
1週間 パフォーマンス:
+5.94%
1か月 パフォーマンス:
+5.25%
6か月 パフォーマンス:
-2.85%
1年 パフォーマンス:
+16.23%
1日の値動き範囲:
$93.35
$97.40
1週間の範囲:
$90.05
$97.40
52週間の値動き範囲:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
ALC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
96.80 | 47.88B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
507.90 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
228.71 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
222.62 | 32.70B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.70 | 17.29B | 17.28B | 108.00M | 391.00M | 0.20 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-01-24 | 繰り返されました | Needham | Buy |
| 2025-01-10 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | 繰り返されました | Needham | Buy |
| 2024-11-12 | 繰り返されました | Needham | Buy |
| 2024-10-10 | アップグレード | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-04-10 | 開始されました | Goldman | Buy |
| 2024-03-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | 開始されました | Bernstein | Outperform |
| 2023-12-18 | ダウングレード | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | アップグレード | Societe Generale | Sell → Hold |
| 2022-12-22 | 開始されました | Mizuho | Buy |
| 2022-11-17 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-08-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-05-13 | 再開されました | Credit Suisse | Outperform |
| 2022-05-12 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | 開始されました | Needham | Buy |
| 2022-03-11 | 開始されました | BofA Securities | Buy |
| 2022-01-18 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | 開始されました | Oppenheimer | Perform |
| 2021-07-14 | 開始されました | Deutsche Bank | Buy |
| 2021-05-06 | アップグレード | Citigroup | Sell → Neutral |
| 2021-03-22 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-11-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-07-06 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-07-06 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | アップグレード | Argus | Hold → Buy |
| 2020-03-24 | アップグレード | Societe Generale | Sell → Hold |
| 2020-03-13 | アップグレード | UBS | Neutral → Buy |
| 2020-03-05 | 開始されました | Citigroup | Neutral |
| 2020-02-26 | アップグレード | Berenberg | Hold → Buy |
| 2020-01-08 | 開始されました | Argus | Hold |
| 2019-10-29 | 開始されました | Stephens | Equal-Weight |
| 2019-08-21 | 繰り返されました | BofA/Merrill | Neutral |
| 2019-06-24 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-06-14 | 開始されました | BTIG Research | Neutral |
| 2019-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-05-02 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Alcon Inc (ALC) 最新ニュース
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - Vision Monday
Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar
All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion - BioPharma Dive
Alcon claims control of cell therapy firm Aurion - pharmaphorum
Alcon acquires majority interest in Aurion Biotech - Ophthalmology Times
Alcon secures majority stake in Aurion, deposes CEO - PharmaLive
Related Content: Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon to buy Lensar in deal worth up to $430M - The Business Journals
Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon upgraded at BofA Securities to Buy on earnings growth potential - MSN
Alcon acquires majority interest in Aurion Biotech to advance first-ever corneal cell therapy candidate - BSA bureau
Aurion CEO is out as Alcon takes majority stake in cell therapy startup - Endpoints News
Alcon acquires majority stake in Aurion Biotech By Investing.com - Investing.com South Africa
Alcon buys majority stake in Aurion Biotech (ALC:NYSE) - Seeking Alpha
Alcon acquires majority stake in Aurion Biotech - Investing.com
Alcon Acquires Majority Interest In Aurion Biotech, Inc. To Advance Innovative Cell Therapy For Corneal Endothelial Disease - Marketscreener.com
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Business Wire
Stifel maintains Alcon stock Buy rating, $100 price target By Investing.com - Investing.com Australia
Stifel maintains Alcon stock Buy rating with $100 target By Investing.com - Investing.com Australia
Bernstein maintains Alcon Outperform rating, $110.50 target - Investing.com
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Alcon Gets EU Nod for Clareon Vivity Intraocular Lens - MPO-mag
Alcon signs merger agreement to acquire Lensar - Medical Device Network
Bank of America Upgrades Alcon (ALC) Stock Rating Amid Growth Pr - GuruFocus.com
HSBC and BofA have differing views on Alcon ahead of product launches - TradingView
ALC Stock Rises Following the Merger Agreement With LENSAR - TradingView
Stifel maintains Alcon stock Buy rating, $100 price target - Investing.com India
BofA raises Alcon stock rating, boosts target to CHF96 By Investing.com - Investing.com South Africa
Alcon agrees to purchase LENSAR - Ophthalmology Times
BofA raises Alcon stock rating, boosts target to CHF96 - Investing.com India
Switzerland: Alcon agrees acquisition of Lensar for up to US$430m - Investors in Healthcare
Alcon Gets CE Mark for Clareon Vivity Intraocular Lens - Marketscreener.com
Alcon to Begin Commercial Rollout of Vivity Lens in Europe by Q2 - Marketscreener.com
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities - Business Wire
Alcon Agrees to Acquire Lensar, Inc. for Up to $430 Million - Vision Monday
BTIG cuts LENSAR stock rating post Alcon acquisition deal - Investing.com India
BTIG cuts LENSAR stock rating post Alcon acquisition deal By Investing.com - Investing.com Australia
Latham & Watkins Represents LENSAR, Inc. in Acquisition by Alcon - Latham & Watkins LLP
Alcon to Acquire LENSAR in $430M Deal - USA Herald
Alcon to acquire Lensar for up to $430M - BioWorld Online
Norton Rose, Latham Steer Alcon's $430M Lensar Buy - Law360
Alcon agrees to acquire LENSAR for $14.00 per share - MSN
Alcon to acquire LENSAR for up to $430 million By Investing.com - Investing.com South Africa
Swiss Stocks Start Week in the Red; Alcon Shares Rise - TradingView
Alcon Eyes Surgical Edge With LENSAR Buyout: Details - Benzinga
Switzerland's Alcon to Buy US-based Medical Technology Group Lensar -March 24, 2025 at 09:48 am EDT - Marketscreener.com
Alcon to Acquire Lensar for $430 Million -March 24, 2025 at 08:42 am EDT - Marketscreener.com
Alcon to acquire LENSAR for up to $430 million - Investing.com
LENSAR Announces Merger Agreement with Alcon - TipRanks
Alcon Inc (ALC) 財務データ
収益
当期純利益
現金流量
EPS
0.33%
大文字化:
|
ボリューム (24 時間):